secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0000950170-23-051526
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences cuts workforce 41%, appoints Christopher Kirk as CEO, extends cash runway to late 2026
--------------------------------------------------------------------------------

- Workforce reduction of ~41%, pausing all research and drug discovery; severance charge of $2.9M-$3.2M expected in Q4 2023.
- CEO John Fowler resigns Nov 7; co-founder Christopher Kirk appointed CEO with $600k salary, $75k bonus, 875k stock options.
- CMO Noreen Roth Henig steps down Oct 6; Zung To assumes clinical operations oversight.
- Cash runway extended to late 2026; PALIZADE Phase 2b LN data mid-2026. KZR-261 Phase 1 data 2024, PORTOLA AIH data mid-2025.
- Exploring strategic partnering for protein secretion platform and preclinical programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/0000950170-23-051526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023051526/kzr-20230930.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer